CF Foundation Awards $3.5M to Develop Antibiotic ACG-701

The Cystic Fibrosis Foundation has awarded up to $3.5 million to Aceragen to support the clinical development of ACG-701, an investigational antibiotic to treat pulmonary exacerbations in people with cystic fibrosis (CF).

Aceragen Announces $3.5 Million Development Award from Cystic Fibrosis Foundation to Progress Novel Therapy for CF-Related Exacerbations

Agreement supports late-stage clinical study for ACG-701 beginning in 2022 Advances Aceragen’s development effort to treat life-threatening rare and orphan diseases RALEIGH-DURHAM, NC – January 06, 2022 – Aceragen, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for orphan diseases with high unmet medical need, today announced that its wholly-owned subsidiary, Arrevus, Inc., has received